173 related articles for article (PubMed ID: 30648509)
1. Zoledronic Acid Inhibits the RhoA-mediated Amoeboid Motility of Prostate Cancer Cells.
Pietrovito L; Comito G; Parri M; Giannoni E; Chiarugi P; Taddei ML
Curr Cancer Drug Targets; 2019; 19(10):807-816. PubMed ID: 30648509
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid impairs stromal reactivity by inhibiting M2-macrophages polarization and prostate cancer-associated fibroblasts.
Comito G; Pons Segura C; Taddei ML; Lanciotti M; Serni S; Morandi A; Chiarugi P; Giannoni E
Oncotarget; 2017 Jan; 8(1):118-132. PubMed ID: 27223431
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic Acid Enhanced the Antitumor Effect of Cisplatin on Orthotopic Osteosarcoma by ROS-PI3K/AKT Signaling and Attenuated Osteolysis.
Liu L; Geng H; Mei C; Chen L
Oxid Med Cell Longev; 2021; 2021():6661534. PubMed ID: 33859780
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of zoledronic acid for the elimination of disseminated tumor cells in a clinically relevant, spontaneously metastatic prostate cancer xenograft model.
Böckelmann LC; Freytag V; Ahlers AK; Maar H; Gosau T; Baranowsky A; Schmitz R; Pantel K; Schumacher U; Haider MT; Lange T
Bone; 2023 Jun; 171():116741. PubMed ID: 36934984
[TBL] [Abstract][Full Text] [Related]
5. Arachidonic acid induction of Rho-mediated transendothelial migration in prostate cancer.
Brown M; Roulson JA; Hart CA; Tawadros T; Clarke NW
Br J Cancer; 2014 Apr; 110(8):2099-108. PubMed ID: 24595005
[TBL] [Abstract][Full Text] [Related]
6. Molecular and cellular mechanisms for zoledronic acid-loaded magnesium-strontium alloys to inhibit giant cell tumors of bone.
Li M; Wang W; Zhu Y; Lu Y; Wan P; Yang K; Zhang Y; Mao C
Acta Biomater; 2018 Sep; 77():365-379. PubMed ID: 30030174
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms.
Quinn JE; Brown LG; Zhang J; Keller ET; Vessella RL; Corey E
Prostate Cancer Prostatic Dis; 2005; 8(3):253-9. PubMed ID: 15999121
[TBL] [Abstract][Full Text] [Related]
9. Targeting cathepsin K diminishes prostate cancer establishment and growth in murine bone.
Liang W; Wang F; Chen Q; Dai J; Escara-Wilke J; Keller ET; Zimmermann J; Hong N; Lu Y; Zhang J
J Cancer Res Clin Oncol; 2019 Aug; 145(8):1999-2012. PubMed ID: 31172267
[TBL] [Abstract][Full Text] [Related]
10. Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration.
Odri G; Kim PP; Lamoureux F; Charrier C; Battaglia S; Amiaud J; Heymann D; Gouin F; Redini F
BMC Cancer; 2014 Mar; 14():169. PubMed ID: 24612486
[TBL] [Abstract][Full Text] [Related]
11. Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review.
Wang L; Fang D; Xu J; Luo R
BMC Cancer; 2020 Nov; 20(1):1059. PubMed ID: 33143662
[TBL] [Abstract][Full Text] [Related]
12. Prior administration of vitamin K2 improves the therapeutic effects of zoledronic acid in ovariectomized rats by antagonizing zoledronic acid-induced inhibition of osteoblasts proliferation and mineralization.
Zhao B; Zhao W; Wang Y; Zhao Z; Zhao C; Wang S; Gao C
PLoS One; 2018; 13(8):e0202269. PubMed ID: 30125322
[TBL] [Abstract][Full Text] [Related]
13. Self-assembling nanoparticles encapsulating zoledronic acid inhibit mesenchymal stromal cells differentiation, migration and secretion of proangiogenic factors and their interactions with prostate cancer cells.
Borghese C; Casagrande N; Pivetta E; Colombatti A; Boccellino M; Amler E; Normanno N; Caraglia M; De Rosa G; Aldinucci D
Oncotarget; 2017 Jun; 8(26):42926-42938. PubMed ID: 28477013
[TBL] [Abstract][Full Text] [Related]
14. Drugs which inhibit osteoclast function suppress tumor growth through calcium reduction in bone.
Li X; Liao J; Park SI; Koh AJ; Sadler WD; Pienta KJ; Rosol TJ; McCauley LK
Bone; 2011 Jun; 48(6):1354-61. PubMed ID: 21419883
[TBL] [Abstract][Full Text] [Related]
15. Targeting the {alpha} receptor for platelet-derived growth factor as a primary or combination therapy in a preclinical model of prostate cancer skeletal metastasis.
Russell MR; Liu Q; Fatatis A
Clin Cancer Res; 2010 Oct; 16(20):5002-10. PubMed ID: 20813817
[TBL] [Abstract][Full Text] [Related]
16. Mature and progenitor endothelial cells perform angiogenesis also under protease inhibition: the amoeboid angiogenesis.
Chillà A; Margheri F; Biagioni A; Del Rosso M; Fibbi G; Laurenzana A
J Exp Clin Cancer Res; 2018 Apr; 37(1):74. PubMed ID: 29615071
[TBL] [Abstract][Full Text] [Related]
17. Zoledronic acid blocks the interaction between breast cancer cells and regulatory T-cells.
Liu H; Wang SH; Chen SC; Chen CY; Lin TM
BMC Cancer; 2019 Feb; 19(1):176. PubMed ID: 30808421
[TBL] [Abstract][Full Text] [Related]
18. Dual Targeting of Mesenchymal and Amoeboid Motility Hinders Metastatic Behavior.
Jones BC; Kelley LC; Loskutov YV; Marinak KM; Kozyreva VK; Smolkin MB; Pugacheva EN
Mol Cancer Res; 2017 Jun; 15(6):670-682. PubMed ID: 28235899
[TBL] [Abstract][Full Text] [Related]
19. The prostate metastasis suppressor gene NDRG1 differentially regulates cell motility and invasion.
Sharma A; Mendonca J; Ying J; Kim HS; Verdone JE; Zarif JC; Carducci M; Hammers H; Pienta KJ; Kachhap S
Mol Oncol; 2017 Jun; 11(6):655-669. PubMed ID: 28371345
[TBL] [Abstract][Full Text] [Related]
20. RASSF1C oncogene elicits amoeboid invasion, cancer stemness, and extracellular vesicle release via a SRC/Rho axis.
Tognoli ML; Vlahov N; Steenbeek S; Grawenda AM; Eyres M; Cano-Rodriguez D; Scrace S; Kartsonaki C; von Kriegsheim A; Willms E; Wood MJ; Rots MG; van Rheenen J; O'Neill E; Pankova D
EMBO J; 2021 Oct; 40(20):e107680. PubMed ID: 34532864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
